Actively Recruiting
Phase 1 Study of Arlocabtagene Autoleucel in Combination With New Drugs for Adults With Relapsed or Refractory Multiple Myeloma
Led by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Updated on 2026-07-16
187
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This trial focuses on participants with relapsed andor refractory multiple myeloma RRMM. It aims to find a safe and tolerable dose of arlocabtagene autoleucel BMS-986393 when combined with other investigational drugs including alnuctamab, mezigdomide, iberdomide, and elranatamab. The study is a Phase 1, open-label, multicenter trial designed to evaluate safety and preliminary efficacy while determining the recommended dose for each combination. Participants receive arlocabtagene autoleucel along with one or more of the investigational drugs alnuctamab, mezigdomide, iberdomide, elranatamab, or mezigdomide with dexamethasone. Each drug is administered at specified doses on specified days. The study follows a sequential model and includes multiple experimental arms, each testing a different combination of these drugs. During the study, participants are closely monitored for adverse events and safety outcomes over two years, including serious events and events of special interest. Researchers will also assess the overall response rate and other measures of treatment effectiveness. Blood samples will be collected to measure drug concentration over time. The study will establish the recommended Phase 2 dose and track participant health for up to two years after treatment.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
